Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)

NCT04506086 · clinicaltrials.gov ↗
PHASE4
Phase
TERMINATED
Status
10
Enrollment
INDUSTRY
Sponsor class

Stopped The decision to terminate is not based on safety or efficacy but due to slow enrollment impacting the ability to complete the study as planned.

Conditions

Interventions

Sponsor

Amgen